|
|
|
|
Document Preview Asset Purchase Agreement |
||||
|
|
||||
|
Click "Add to Cart" button to purchase document. |
||||
|
|
||||
|
Title: |
Asset Purchase Agreement |
|||
|
Entities: |
||||
|
Date: |
2007 |
|||
|
Size: |
Preview shows 65KB of 279KB total |
|||
|
Price: |
$68 |
|||
|
ID: |
#3023197 |
|||
|
|
||||
|
||||
|
|
||||
|
Start of Preview |
||||
EXECUTION VERSION
ASSET PURCHASE AGREEMENT
by and among
NABI BIOPHARMACEUTICALS,
BIOTEST PHARMACEUTICALS CORPORATION
and
BIOTEST AG
Dated as of September 11, 2007
TABLE OF CONTENTS
| Page | ||||
| ARTICLE I DEFINITIONS | 1 | |||
| 1.1 |
Definitions. |
1 | ||
| 1.2 |
Other Definitional Provisions. |
1 | ||
| ARTICLE II PURCHASE AND SALE | 2 | |||
| 2.1 |
Purchase and Sale of Purchased Assets. |
2 | ||
| 2.2 |
Excluded Assets. |
3 | ||
| 2.3 |
Assumed Liabilities. |
4 | ||
| 2.4 |
Excluded Liabilities. |
6 | ||
| 2.5 |
Consent of Third Parties. |
7 | ||
| 2.6 |
Purchase Price; Escrow. |
8 | ||
| 2.7 |
Accounts Receivable. |
9 | ||
| 2.8 |
Inventory. |
9 | ||
| 2.9 |
Purchase Price Allocation. |
11 | ||
| 2.10 |
No Set-Off. |
11 | ||
| 2.11 |
Risk of Loss. |
12 | ||
| ARTICLE III CLOSING | 12 | |||
| 3.1 |
Closing. |
12 | ||
| 3.2 |
Transactions at Closing. |
12 | ||
| ARTICLE IV REPRESENTATIONS AND WARRANTIES OF SELLER | 16 | |||
| 4.1 |
Organization. |
16 | ||
| 4.2 |
Due Authorization. |
16 | ||
| 4.3 |
Organizational Documents. |
17 | ||
| 4.4 |
No Conflicts; Enforceability. |
17 | ||
| 4.5 |
Title; Sufficiency. |
17 | ||
| 4.6 |
Inventory; Equipment. |
18 | ||
| 4.7 |
Intellectual Property. |
18 | ||
| 4.8 |
Litigation. |
19 | ||
| 4.9 |
Government Consents. |
20 | ||
| 4.10 |
Third Party Consents. |
20 | ||
| 4.11 |
Taxes. |
20 | ||
| 4.12 |
Real Property. |
21 | ||
| 4.13 |
Personal Property and Equipment. |
23 | ||
| 4.14 |
Environmental, Safety and Health. |
23 | ||
| 4.15 |
Employee Benefit Plans. |
24 | ||
| 4.16 |
Compliance with Laws. |
26 | ||
| 4.17 |
Regulatory Matters. |
26 | ||
| 4.18 |
Contracts. |
27 | ||
| 4.19 |
Financial Statements. |
29 | ||
i
| 4.20 |
Accounts Receivable. |
30 | ||
| 4.21 |
Absence of Certain Changes. |
30 | ||
| 4.22 |
Brokers, Etc. |
31 | ||
| 4.23 |
Insurance. |
31 | ||
| 4.24 |
Compensation and Status of Employees. |
32 | ||
| 4.25 |
Customers and Suppliers. |
33 | ||
| 4.26 |
FDA Approval of the Boca Raton Facility. |
33 | ||
| 4.27 |
Product Regulatory Status. |
34 | ||
| 4.28 |
Return Policy. |
34 | ||
| 4.29 |
Disclaimer. |
34 | ||
| ARTICLE V REPRESENTATIONS AND WARRANTIES OF BUYER AND PARENT | 35 | |||
| 5.1 |
Organization. |
35 | ||
| 5.2 |
Due Authorization. |
35 | ||
| 5.3 |
No Conflicts; Enforceability. |
35 | ||
| 5.4 |
Litigation. |
36 | ||
| 5.5 |
Consents. |
36 | ||
| 5.6 |
Financing. |
36 | ||
| 5.7 |
Government Authorizations. |
36 | ||
| 5.8 |
Brokers, Etc. |
37 | ||
| 5.9 |
Independent Investigation. |
37 | ||
| ARTICLE VI COVENANTS PRIOR TO CLOSING | 37 | |||
| 6.1 |
Access to Information. |
37 | ||
| 6.2 |
Conduct of the Biologics SBU. |
37 | ||
| 6.3 |
Required Notices, Approvals and Consents. |
40 | ||
| 6.4 |
HSR Act; Other Antitrust Laws. |
40 | ||
| 6.5 |
Proxy Statement; Seller Stockholders? Meeting. |
41 | ||
| 6.6 |
No Solicitation; Acquisition Proposals. |
42 | ||
| 6.7 |
Transition Activities. |
43 | ||
| 6.8 |
Notifications; Updated Schedules. |
45 | ||
| 6.9 |
Further Assurances; Further Documents. |
46 | ||
| 6.10 |
Inventory. |
47 | ||
| 6.11 |
Buyer Financing. |
47 | ||
| ARTICLE VII CONDITIONS TO CLOSING | 47 | |||
| 7.1 |
Conditions Precedent to Obligations of Buyer and Seller. |
47 | ||
| 7.2 |
Conditions Precedent to Buyer?s Obligations. |
47 | ||
| 7.3 |
Conditions Precedent to Seller?s Obligations. |
48 | ||
| ARTICLE VIII ADDITIONAL COVENANTS | 49 | |||
| 8.1 |
Confidentiality; Publicity. |
49 | ||
| 8.2 |
Availability of Records. |
49 | ||
| 8.3 |
Use of Trade or Service Marks; Name Change. |
50 | ||
ii
| 8.4 |
Notification of Customers. |
50 | ||
| 8.5 |
Products Returns, Rebate Charges and Wholesaler Charges. |
51 | ||
| 8.6 |
Accounts Receivable. |
51 | ||
| 8.7 |
Regulatory Matters. |
52 | ||
| 8.8 |
Website Information. |
53 | ||
| 8.9 |
Tax Matters. |
53 | ||
| 8.10 |
Insurance. |
54 | ||
| 8.11 |
Right of First Negotiation and First Refusal. |
54 | ||
| ARTICLE IX EMPLOYEE MATTERS | 54 | |||
| 9.1 |
Employee Transfer. |
54 | ||
| 9.2 |
Benefits. |
55 | ||
| 9.3 |
Employee Information. |
56 | ||
| ARTICLE X TERMINATION AND SURVIVAL | 56 | |||
| 10.1 |
Termination. |
56 | ||
| 10.2 |
Procedure and Effect of Termination. |
58 | ||
| ARTICLE XI INDEMNIFICATION | 59 | |||
| 11.1 |
Survival of Representations, Warranties and Covenants. |
59 | ||
| 11.2 |
Indemnification by Seller. |
59 | ||
| 11.3 |
Indemnification by Buyer. |
60 | ||
| 11.4 |
Recoupment Against Escrow Agreement. |
61 | ||
| 11.5 |
Calculation of Losses; Treatment of Indemnification Payments. |
61 | ||
| 11.6 |
Termination of Indemnification. |
62 | ||
| 11.7 |
Procedures. |
62 | ||
| 11.8 |
Sole Remedy; No Additional Representations. |
64 | ||
| 11.9 |
Limitations on Liability. |
64 | ||
| ARTICLE XII MISCELLANEOUS | 64 | |||
| 12.1 |
Assignment; Binding Effect. |
64 | ||
| 12.2 |
Expenses. |
65 | ||
| 12.3 |
Notices. |
65 | ||
| 12.4 |
Severability. |
66 | ||
| 12.5 |
Entire Agreement. |
66 | ||
| 12.6 |
No Third-Party Beneficiaries. |
66 | ||
| 12.7 |
Waiver. |
67 | ||
| 12.8 |
Governing Law; Arbitration. |
67 | ||
| 12.9 |
Injunctive Relief. |
67 | ||
| 12.10 |
Headings. |
68 | ||
| 12.11 |
Counterparts. |
68 | ||
| 12.12 |
Construction. |
68 | ||
| 12.13 |
Parent Guaranty. |
68 | ||
iii
ANNEX AND EXHIBITS
|
Annex 1.1 |
Definitions | |
|
Exhibit 1.1(a) |
Assignment and Assumption Agreement | |
|
Exhibit 1.1(b) |
Assignment of BSBU Intellectual Property | |
|
Exhibit 1.1(c) |
Bill of Sale | |
|
Exhibit 1.1(d) |
Buyer Registration Transfer Letter | |
|
Exhibit 1.1(e) |
Seller Registration Transfer Letter | |
|
Exhibit 6.7(b) |
Transition Services Agreement | |
|
Exhibit 6.7(c) |
Contract Manufacturing Agreement | |
|
Exhibit 8.3(b) |
Trademark License Agreement | |
|
Exhibit 8.11 |
Right of First Refusal Agreement | |
iv
ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT (this ?Agreement?), dated as of September 11, 2007 (the ?Execution Date?), is entered into by and among Nabi Biopharmaceuticals, a Delaware corporation (?Seller?), Biotest Pharmaceuticals Corporation, a Delaware corporation (?Buyer?), and Biotest AG, a company organized under the laws of Germany (?Parent?). Each of Seller, Buyer and Parent are sometimes referred to herein, individually, as ?Parties? and, collectively, as the ?Parties.? All capitalized terms used herein shall have the meanings specified in Annex 1.1 or elsewhere in this Agreement, as applicable.
RECITALS
WHEREAS, Seller owns certain assets relating to, used in or necessary for the development, manufacture, distribution, marketing and sale of biologics Products, and that together comprise the Biologics Strategic Business Unit (the ?Biologics SBU?) and certain other assets of Seller as described herein; and
WHEREAS, subject to the terms and conditions of this Agreement, Seller wishes to sell the Purchased Assets to Buyer, and Buyer wishes to purchase the Purchased Assets and assume the Assumed Liabilities from Seller.
NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants, agreements and provisions set forth herein and in the Other Agreements, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties agree as follows:
ARTICLE I
DEFINITIONS
1.1 Definitions. Except as otherwise expressly provided, capitalized terms used in this Agreement shall have the meanings set forth in Annex 1.1.
1.2 Other Definitional Provisions.
(a) When a reference is made in this Agreement to an Article, Section, Exhibit, Schedule, Recital or Preamble, such reference is to an Article, Section, Exhibit, Schedule, Recital or Preamble of or to this Agreement unless otherwise indicated.
(b) The words ?hereof,? ?herein,? ?hereto? and ?hereunder? and words of similar import, when used in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.
(c) The terms defined in the singular has a comparable meaning when used in the plural, and vice versa.
(d) Words of one gender include the other gender.
(e) References to a Person are also to its successors and permitted assigns.
(f) The term ?dollars? and ?$? means United States dollars.
(g) The word ?including? means ?including without limitation? and the words ?include? and ?includes? have corresponding meanings.
(h) The phrase ?delivered to Buyer? means either delivery to Buyer in paper or electronic form or by posting of the applicable material in the Data Room.
(i) The phrases ?arise after the Effective Time? and ?arising after the Effective Time? mean ?in respect of facts, circumstances or events occurring after the Effective Time.?
ARTICLE II
PURCHASE AND SALE
2.1 Purchase and Sale of Purchased Assets. At the Effective Time, on the terms and subject to the conditions hereof and in consideration of the Purchase Price to be paid to Seller by Buyer, Seller will sell, convey, transfer, assign and deliver to Buyer, free and clear of all Encumbrances other than the Permitted Encumbrances, and Buyer will purchase, take delivery of and acquire from Seller, all of Seller?s right, title and interest in and to the following Assets:
(a) all Assets of Seller relating to, used in or necessary for the operation of the Biologics SBU or the development, manufacture, distribution, marketing or sale of the Products, including the Assigned Contracts, the Inventory, the BSBU Prepaid Expenses, the BSBU Goodwill, the BSBU Licenses, the Registrations, the Promotional Materials, the Applicable Permits, the BSBU Equipment, the BSBU Personal Property Leases, the BSBU Records, the BSBU Intellectual Property, the Facilities, the Centers, the BSBU Real Property and the BSBU Real Property Leases;
(b) the Corporate Shared Services Assets;
(c) the vacant real property located at 5800 Park of Commerce Boulevard NW, Boca Raton, Florida, with parcel number 06434706030140000;
(d) any refund or credit of Taxes attributable to any Assumed Tax Liability; and
(e) (i) the Buyer Shared Use Assets not split or segregated pursuant to Section 6.7(d), (ii) to the extent split or segregated pursuant to Section 6.7(d), the split or segregated portion of any Buyer Shared Use Asset agreed to by the Parties to be owned or held by Buyer after the Effective Time, and (iii) to the extent split or segregated pursuant to Section 6.7(d), the split or segregated portion of any Seller Shared Use Asset agreed by the Parties to be owned or held by Buyer after the Effective Time;
(collectively, the ?Purchased Assets?), including (x) all goodwill relating thereto, (y) all rights in and to all warranties, guarantees, indemnities, causes of action and similar rights with respect
|
End of Preview |
Home Intelligence Services Subscriptions News About Us